{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:51:02Z","timestamp":1777107062939,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.brainres.2025.149788","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:48:25Z","timestamp":1750168105000},"page":"149788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Fatigue in natalizumab-treated Multiple Sclerosis patients: How much is wearing-off to blame?"],"prefix":"10.1016","volume":"1864","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-8354","authenticated-orcid":false,"given":"Giuseppe","family":"Magro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Pascarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro Antonio","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Spano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda","family":"Buonocore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cataldo","family":"Mummolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Di","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Saraceno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2025.149788_b0005","article-title":"Fatigue profiles in patients with multiple sclerosis are based on severity of fatigue and not on dimensions of fatigue","volume":"10(1):4167","author":"Beckerman","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.brainres.2025.149788_b0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1037\/a0019585","article-title":"Frontal networks play a role in fatigue perception in multiple sclerosis","volume":"124","author":"Pardini","year":"2010","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.brainres.2025.149788_b0015","doi-asserted-by":"crossref","unstructured":"Pardini M, Bonzano L, Roccatagliata L, Mancardi GL, Bove M. The fatigue-motor performance paradox in multiple sclerosis. Sci Rep 2013;3:2001. (In eng). DOI: 10.1038\/srep02001.","DOI":"10.1038\/srep02001"},{"issue":"7","key":"10.1016\/j.brainres.2025.149788_b0020","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2025.149788_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122930","article-title":"Natalizumab extended interval dosing: what about wearing-off effect?","volume":"458","author":"Bernardes","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.brainres.2025.149788_b0030","doi-asserted-by":"crossref","unstructured":"Cath\u00e9rine D, Annelien P, Anne S, et al. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines? Mult Scler Relat Disord 2020;41:102020. (In eng). DOI: 10.1016\/j.msard.2020.102020.","DOI":"10.1016\/j.msard.2020.102020"},{"key":"10.1016\/j.brainres.2025.149788_b0035","doi-asserted-by":"crossref","unstructured":"Toorop AA, van Lierop Z, Strijbis EMM, et al. The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis. Mult Scler Relat Disord 2022;57:103364. (In eng). DOI: 10.1016\/j.msard.2021.103364.","DOI":"10.1016\/j.msard.2021.103364"},{"key":"10.1016\/j.brainres.2025.149788_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.nerep.2023.100167","article-title":"Wearing-off phenomenon in multiple sclerosis patients on ofatumumab: a case series","volume":"3","author":"Labani","year":"2023","journal-title":"Neuroimmunology Reports"},{"key":"10.1016\/j.brainres.2025.149788_b0045","doi-asserted-by":"crossref","unstructured":"Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S. Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic. J Neurol Sci 2021;429:117622. (In eng). DOI: 10.1016\/j.jns.2021.117622.","DOI":"10.1016\/j.jns.2021.117622"},{"issue":"17","key":"10.1016\/j.brainres.2025.149788_b0050","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.brainres.2025.149788_b0055","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000678","article-title":"Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy","volume":"7","author":"Bringeland","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.brainres.2025.149788_b0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2014.139","article-title":"The link between multiple sclerosis and depression","volume":"10","author":"Feinstein","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.brainres.2025.149788_b0065","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/1352458520972279","article-title":"Fatigue, depression, and pain in multiple sclerosis: how neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms","volume":"28","author":"Heitmann","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.brainres.2025.149788_b0070","doi-asserted-by":"crossref","unstructured":"Tarasiuk J, Kapica-Topczewska K, Czarnowska A, Chor\u0105\u017cy M, Kochanowicz J, Ku\u0142akowska A. Co-occurrence of Fatigue and Depression in People With Multiple Sclerosis: A Mini-Review. Front Neurol 2021;12:817256. (In eng). DOI: 10.3389\/fneur.2021.817256.","DOI":"10.3389\/fneur.2021.817256"},{"issue":"2","key":"10.1016\/j.brainres.2025.149788_b0075","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00415-022-11408-0","article-title":"Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic","volume":"270","author":"Magro","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.brainres.2025.149788_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102533","article-title":"Chronic fatigue and depression due to multiple sclerosis: immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways","volume":"46","author":"Ormstad","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.brainres.2025.149788_b0085","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1007\/s00415-022-11143-6","article-title":"Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping","volume":"269","author":"Sparasci","year":"2022","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.brainres.2025.149788_b0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jnnp-2022-330109","article-title":"Monoaminergic network abnormalities: a marker for multiple sclerosis-related fatigue and depression","volume":"94","author":"Carotenuto","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.brainres.2025.149788_b0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13760-013-0198-2","article-title":"Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex","volume":"113","author":"Ghajarzadeh","year":"2013","journal-title":"Acta Neurol. Belg."},{"issue":"12","key":"10.1016\/j.brainres.2025.149788_b0100","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/1352458509348519","article-title":"The fatigue scale for motor and cognitive functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue","volume":"15","author":"Penner","year":"2009","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.brainres.2025.149788_b0105","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s13760-023-02222-0","article-title":"Validation of persian multiple sclerosis quality of life-29 (P-MSQOL-29) questionnaire","volume":"123","author":"Hassanzadeh","year":"2023","journal-title":"Acta Neurol. Belg."},{"issue":"11","key":"10.1016\/j.brainres.2025.149788_b0110","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1177\/1352458518776583","article-title":"Reliability and acceptability of the multiple sclerosis quality of Life-29 questionnaire in an english-speaking cohort","volume":"25","author":"Baker","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.brainres.2025.149788_b0115","doi-asserted-by":"crossref","unstructured":"Whisman MA, Perez JE, Ramel W. Factor structure of the Beck Depression Inventory-Second Edition (BDI-II) in a student sample. J Clin Psychol 2000;56(4):545-51. (In eng). DOI: 10.1002\/(sici)1097-4679(200004)56:4<545::aid-jclp7>3.0.co;2-u.","DOI":"10.1002\/(SICI)1097-4679(200004)56:4<545::AID-JCLP7>3.0.CO;2-U"},{"issue":"4","key":"10.1016\/j.brainres.2025.149788_b0120","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/ene.12932","article-title":"Psychometric properties and validity of Beck depression inventory II in multiple sclerosis","volume":"23","author":"Sacco","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.brainres.2025.149788_b0125","doi-asserted-by":"crossref","unstructured":"Valente G, Diotaiuti P, Corrado S, Tosti B, Zanon A, Mancone S. Validity and measurement invariance of abbreviated scales of the State-Trait Anxiety Inventory (STAI-Y) in a population of Italian young adults. Front Psychol 2025;16:1443375. (In eng). DOI: 10.3389\/fpsyg.2025.1443375.","DOI":"10.3389\/fpsyg.2025.1443375"},{"issue":"6","key":"10.1016\/j.brainres.2025.149788_b0130","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ane.12564","article-title":"Anxiety in multiple sclerosis: psychometric properties of the state-trait anxiety inventory","volume":"134","author":"Santangelo","year":"2016","journal-title":"Acta Neurol. Scand."},{"issue":"7","key":"10.1016\/j.brainres.2025.149788_b0135","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1177\/1352458508090923","article-title":"Repeated assessment of neuropsychological deficits in multiple sclerosis using the symbol digit modalities test and the MS neuropsychological screening questionnaire","volume":"14","author":"Benedict","year":"2008","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.brainres.2025.149788_b0140","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.brainres.2025.149788_b0145","doi-asserted-by":"crossref","unstructured":"Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry 2013;35(4):416-31. (In eng). DOI: 10.1590\/1516-4446-2012-1048.","DOI":"10.1590\/1516-4446-2012-1048"},{"issue":"3","key":"10.1016\/j.brainres.2025.149788_b0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.psychres.2004.03.014","article-title":"Gradations of clinical severity and sensitivity to change assessed with the Beck depression inventory-II in japanese patients with depression","volume":"135","author":"Hiroe","year":"2005","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.brainres.2025.149788_b0155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7224\/1537-2073.2013-013","article-title":"Validation of mood measures for people with multiple sclerosis","volume":"16","author":"Watson","year":"2014","journal-title":"International Journal of MS Care"},{"issue":"6","key":"10.1016\/j.brainres.2025.149788_b0160","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/jnnp-2018-320050","article-title":"Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis","volume":"90","author":"Manjaly","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.brainres.2025.149788_b0165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7224\/1537-2073.2013-017","article-title":"Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle","volume":"16","author":"Ratchford","year":"2014","journal-title":"Int J MS Care"},{"issue":"3","key":"10.1016\/j.brainres.2025.149788_b0170","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000706","article-title":"Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker","volume":"7","author":"Foley","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.brainres.2025.149788_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116880","article-title":"Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study","volume":"415","author":"Bringeland","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.brainres.2025.149788_b0180","doi-asserted-by":"crossref","first-page":"17654","DOI":"10.1038\/s41598-024-68322-w","article-title":"Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients with wearing off","volume":"14","author":"Leodori","year":"2024","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.brainres.2025.149788_b0185","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1212\/WNL.0000000000008358","article-title":"Natalizumab wearing-off symptoms: patients with MS on extended interval dosing may not \u201cmind the gap\u201d","volume":"93","author":"Mowry","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2025.149788_b0190","doi-asserted-by":"crossref","unstructured":"Pizzagalli DA, Roberts AC. Prefrontal cortex and depression. Neuropsychopharmacology 2022;47(1):225-246. (In eng). DOI: 10.1038\/s41386-021-01101-7.","DOI":"10.1038\/s41386-021-01101-7"},{"issue":"14","key":"10.1016\/j.brainres.2025.149788_b0195","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1212\/WNL.0b013e3181f612e3","article-title":"Cognitive compensation failure in multiple sclerosis","volume":"75","author":"Bonnet","year":"2010","journal-title":"Neurology"}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000689932500349X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000689932500349X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:22:51Z","timestamp":1777105371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000689932500349X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"alternative-id":["S000689932500349X"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149788","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatigue in natalizumab-treated Multiple Sclerosis patients: How much is wearing-off to blame?","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149788"}}